|Preferred IUPAC name
|Systematic IUPAC name
|Molar mass||227.34 g·mol−1|
|Boiling point||115±0.05°C (liquid oil)|
Except where noted otherwise, data is given for materials in their standard state (at 25 °C (77 °F), 100 kPa)
|what is: / ?)(|
Morphinan has a phenanthrene core structure with the A ring remaining aromatic and the B and C rings being saturated, and an additional nitrogen-containing, six-membered, saturated ring, the D ring, being attached to carbons 9 and 13 of the core, and with the nitrogen at position 17 of the composite.
Of the major naturally-occurring opiates of the morphinan type—morphine, codeine and thebaine—thebaine has no therapeutic properties (it causes seizures in humans), but it provides a low-cost feedstock for the synthesis of at least four semi-synthetic opiates, including hydrocodone, hydromorphone, oxycodone and oxymorphone, and, perhaps more significantly, the opioid antagonist naloxone.
The physiological behavior of morphinans (naturally-occurring and semi-synthetic derivatives) is thought to be associated with the aromatic A ring, the nitrogen-containing D ring and the "bridge" between these two rings formed by carbons 9, 10 and 11 of the core, with the D ring "above" the core (levo).
Small groups are usually found on morphinan derivatives at carbons 3 and 6.
Many such derivatives have an epoxy group between carbons 4 and 5 (i.e., 4,5α-epoxy), thereby forming an E ring.
The substitution of certain bulky groups on nitrogen 17 converts an opioid agonist into an opioid antagonist, the most important of which is naloxone, a pure opioid antagonist with no opioid agonist properties whatsoever.
Addition of a two carbon group between carbons 6 and 14 (e.g., 6,14-ethano, 6,14-etheno, and 6,14-ethyno), and which significantly distorts the C ring, may increase potency 1,000 to 10,000 times, or greater, compared to morphine, as in etorphine, and others. The relative potency is thought to be associated with the degree of distortion of the C ring, and is perhaps greatest in diprenorphine, where this group is α,α-dimethyl-6,14-etheno. Diprenorphine (M5050) is the recommended etorphine (M99) antagonist, but it is not a pure opioid antagonist (i.e., it is also a weak opioid agonist), so naloxone remains a significant therapeutic tool in suspected cases of opioid overdose.
If the D ring is "below" the core (dextro), the analgesic and euphoric properties are eliminated or are dramatically reduced, but the cough-suppressant property is retained, as in dextromethorphan.
Immediate derivatives of morphinan include:
More distant of derivatives include:
As well as the following:
- Morphine (and naturally-occurring and semi-synthetic analogues)
The following structures are related to morphinan:
- Brunton L L, Blumenthal D K, Murri N, Dandan R H, Knollmann B C. Goodman & Gilman's The Pharmacological Basis of Therapeutics. 12th ed. New York: McGraw-Hill, 2011. ISBN 978-0-07-162442-8.